BioDiscovery, a leading Venture Capital Life Sciences Investor, managed by Andera Partners, has agreed to invest $133m in AM-Pharma, a clinical stage biopharmaceutical company. Financial terms were not disclosed. “Raising this amount of capital from highly experienced life sciences venture capital firms LSP and Andera Partners with continued support from existing investors, highlights the urgent medical need in AKI and the potential of recAP as a life-saving treatment. We look forward to working with our expanded investor syndicate and to initiating the Phase III trial.” Erik van den Berg, AM-Pharma CEO.